A crystallisation development workflow for the manufacturability improvement of active pharmaceutical ingredients

Siddique, H. and Hamilton, N. and Robertson, M. and Warzecha, M. and Smith, K. and Brown, C. and Johnston, B. and Florence, A. J. and Douieb, S. and Hadjittofis, E. and Assaf, G. and Carly, N. and Pasha, M. and Cocchini, U. and Mantanus, J. (2022) A crystallisation development workflow for the manufacturability improvement of active pharmaceutical ingredients. In: CMAC Annual Open Day 2022, 2022-05-16 - 2022-05-18.

[thumbnail of Siddique-etal-CMAC-2022-A-crystallisation-development-workflow-for-the-manufacturability-improvement]
Preview
 Text. Filename: Siddique_etal_CMAC_2022_A_crystallisation_development_workflow_for_the_manufacturability_improvement.pdf
Final Published Version
License: Strathprints license 1.0
Download (1MB)| Preview

Abstract

More than 70% active pharmaceutical ingredients (APIs), in the development pipeline, exhibit poor manufacturability (e.g., Isolation, flowability, tabletability) posing major challenges in the production of consistent product with desired performance1. Crystallisation is a key operation in the isolation of the majority of pharmaceuticals and has been demonstrated as a critical process to improve manufacturability of the drug.

Persistent Identifier

https://doi.org/10.17868/strath.00081906
CORE (COnnecting REpositories)